Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
1.180
+0.140 (13.46%)
Jan 23, 2025, 12:41 PM EST - Market open
Veru Inc. Revenue
In the fiscal year ending September 30, 2024, Veru Inc. had annual revenue of $16.89M with 3.62% growth. Veru Inc. had revenue of $6.66M in the quarter ending September 30, 2024, with 72.36% growth.
Revenue (ttm)
$16.89M
Revenue Growth
+3.62%
P/S Ratio
8.31
Revenue / Employee
$80,412
Employees
210
Market Cap
174.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 16.89M | 589.46K | 3.62% |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
VERU News
- 23 days ago - Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business - GlobeNewsWire
- 2 months ago - Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - GlobeNewsWire
- 2 months ago - Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek - GlobeNewsWire
- 3 months ago - Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss - GlobeNewsWire
- 3 months ago - Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress - GlobeNewsWire
- 4 months ago - Veru to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 5 months ago - Veru Inc. (VERU) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results - GlobeNewsWire